Current issue #12, 2016

The state lacks extra-budget for drug coverage

Last week, the issue of drug coverage pilot projects was raised once again. A spokesperson of the Ministry of Economic Development declared that pilot projects needed to be funded through optimization of the available resources, not through extra budget allocations, as it would never be enough money to cover the entire healthcare system. However, there is still a chance that 2 bn RUB-worth extra funding will be allocated for the MoH’s pilot project providing for co-payments for angioplasty patients.

[PharmVestnik # 12, 05/04/2016, p. 1, cont’d p. 3]

Pharma community discussed market trends out of legal status

On March 29, the town of Obninsk (Kaluga region) was the venue of the international forum “Pharma Evolution’2016. Developing an Innovative Environment: Challenges and Prospects” hosted by the Vedomosti newspaper. Nobody questions the fact that the industry continues evolving largely because of an active participation of businesses in the government regulation. However, far from all new trends that businesses are ready to accept have been ultimately captured in legislation. As a result, concurrently with clear-cut development vectors, there emerge initiatives running counter to the main development path, which keeps corporate business plans off balance. In the course of the forum, the spokespersons of the relevant agencies voiced their official positions on the most controversial points.

[PharmVestnik # 12, 05/04/2016, p. 2]

Who is to have responsibility over APIs?

EEC statements shocked Russian API manufacturers

Russian API manufacturers have serious concerns about the Eurasian Economic Commission (EEC) stating that, within the framework of the Eurasian Economic Union (EEU), no procedure will be esta...